Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12230440 | 1.00 | LMNA (0.56) | LMNADNMT1MTORALDH1A1THRB | |
| SCHEMBL2546928 | 1.00 | LMNA (0.56) | LMNADNMT1MTORALDH1A1THRB | |
| SCHEMBL12937918 | 1.00 | LMNA (0.56) | LMNADNMT1MTORALDH1A1THRB | |
| SCHEMBL20129420 | 1.00 | LMNA (0.56) | LMNADNMT1MTORALDH1A1THRB | |
| SCHEMBL6829082 | 0.93 | LMNA (0.58) | LMNADNMT1MTORALDH1A1THRB | |
| SCHEMBL11325017 | 0.91 | LMNA (0.56) | LMNADNMT1MTORALDH1A1THRB | |
| SCHEMBL11316762 | 0.91 | LMNA (0.56) | LMNADNMT1MTORALDH1A1THRB | |
| SCHEMBL11316774 | 0.91 | LMNA (0.56) | LMNADNMT1MTORALDH1A1THRB | |
| SCHEMBL6241747 | 0.90 | LMNA (0.57) | LMNADNMT1MTORALDH1A1THRB | |
| SCHEMBL1138683 | 0.90 | LMNA (0.59) | LMNADNMT1MTORALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536323-B2 | Modified nucleotides | PIERCE BIOTECHNOLOGY, INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-20110262917-A1 | MODIFIED NUCLEOTIDES | PIERCE BIOTECHNOLOGY, INC. (US) | 2011-10-27 | — | — | US | claimed |
| US-20180127822-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | PIERCE BIOTECHNOLOGY, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9828633-B1 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9206216-B2 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2669291-A1 | Modified Nucleotides Methods and Kits | Pierce Biotechnology, Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8536323-B2 | Modified nucleotides | PIERCE BIOTECHNOLOGY, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120252691-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | PIERCE BIOTECHNOLOGY, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110262917-A1 | MODIFIED NUCLEOTIDES | PIERCE BIOTECHNOLOGY, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | disclosed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127822-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | RNGTT, NUDT1, ADAR | LMNA 195/4885DNMT1 69/4885MTOR 4791/4885 |
| US-20120252691-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | RNGTT, NUDT1, ADAR | LMNA 195/4885DNMT1 69/4885MTOR 4791/4885 |
| US-20110262917-A1 | MODIFIED NUCLEOTIDES | NUDT1, RNMT, RNGTT | LMNA 206/4885DNMT1 53/4885MTOR 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.